Source comparison
AOD-9604 vs MOTS-c: Research Application Comparison
Primary Mechanism β3-adrenergic receptor activation → hormone-sensitive lipase activation → triglyceride breakdown in adipocytes AMPK activation + nuclear translocation → metabolic gene upregulation → improved glucose metabolism and mitochondrial function AOD-
This comparison does not assign a generated winner or score.
- Primary Mechanism
- β3-adrenergic receptor activation → hormone-sensitive lipase activation → triglyceride breakdown in adipocytes
- AMPK activation + nuclear translocation → metabolic gene upregulation → improved glucose metabolism and mitochondrial function
- AOD-9604 is direct and peripheral; MOTS-c is systemic and transcriptional.
- Human Clinical Evidence
- Phase 2/3 RCT data in 300+ subjects showing 15-18% visceral fat reduction over 12 weeks at 1mg/day dosing
- No published human RCTs; Phase 1 safety trials ongoing; observational data shows inverse correlation between MOTS-c levels and metabolic dysfunction
- AOD-9604 has reproducible human efficacy data; MOTS-c remains preclinical for outcomes.
- Typical Research Dosing
- 0.5–1.0 mg/day subcutaneous injection, administered once daily in morning fasted state
- 5–15 mg administered 2–3x per week subcutaneous or intramuscular; preclinical models used 0.5 mg/kg in mice
- AOD-9604 requires daily dosing; MOTS-c shows sustained effects with less frequent administration in animal models.
- Primary Research Application
- Studies targeting visceral adipose reduction, body composition during caloric restriction, and metabolic effects of selective lipolysis without hGH side effects
- Investigations of mitochondrial dysfunction, insulin resistance, metabolic syndrome, aging-related metabolic decline, and exercise mimetics
- Choose AOD-9604 for fat-specific research; MOTS-c for metabolic disease mechanisms.
- Side Effect Profile
- Injection-site reactions (22% incidence), rare headache; no glucose dysregulation or IGF-1 elevation observed in trials
- Preclinical data shows no toxicity at 10x therapeutic dose; human safety data pending; theoretically low risk given endogenous production
- AOD-9604's safety is documented in humans; MOTS-c's risk profile is theoretical but appears benign.
- Bottom Line
- Proven tool for lipolysis research with human data; best suited for body composition and adipose-targeted studies
- Emerging metabolic regulator with strong mechanistic rationale but unproven in humans; high potential for insulin resistance and aging research
- If you need documented human fat loss mechanisms, AOD-9604 is the supported choice. If investigating metabolic reprogramming or mitochondrial health, MOTS-c offers a novel pathway worth exploring despite the evidence gap.